Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 643 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lacrimal Apparatus Disease Clear all
Completed Not applicable Interventional

A Study to Evaluate the Safety and Effectiveness of Restylane-Defyne for Punctual Occlusion

NCT03709641
View directory record Official record
Conditions
Mild to Moderate Dry Eye Disease
Interventions
Restylane Defyne
Device
Lead sponsor
John C Meyer, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

NCT01456780
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions
Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acupuncture Treatment of Dry Eye

NCT00554879
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Xeropthalmia
Interventions
Acupuncture, Sham acupuncture
Procedure
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2011 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Closed Eye Neutrophils in Dry Eye Disease

NCT03332342
View directory record Official record
Conditions
Dry Eye, Ocular Inflammation
Interventions
Eye wash
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 1 Interventional

Study Evaluating Techniques for Measuring Tear Production

NCT05497479
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 to be administered in both eyes, Vehicle to be administered in both eyes
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 16, 2026, 10:22 AM EDT
Terminated Phase 4 Interventional Results available

Azithromycin for Meibomian Gland Disease

NCT03953118
View directory record Official record
Conditions
Dry Eye, Neuropathic Eye Pain, Ocular Microbiome, Depression, Anxiety
Interventions
Azithromycin Oral Product, Placebo Oral
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome

NCT05292755
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose (CMC) Artificial Tears, Preservative-free, CMC-free Artificial Tears (control)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 16, 2026, 10:22 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Single Center, Open-Label Study to Evaluate the Ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to Detect Tear Film Stability Utilizing Miebo®

NCT07722624
View directory record Official record
Conditions
Dry Eye
Interventions
Determine the ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to detect tear film stability utilizing Miebo®
Drug
Lead sponsor
The Eye Care Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

NCT01960010
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
MIM-D3 Ophthalmic Solution, Vehicle
Drug
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Waterbury, Connecticut • Lewiston, Maine • Andover, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

NCT04139798
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
NOV03, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Glendale, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator

NCT02798289
View directory record Official record
Conditions
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions
Oculeve Intranasal Neurostimulator
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Artesia, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED

NCT02120079
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Lotemax, Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears), In Vivo Confocal Microscopy (IVCM)
Drug · Diagnostic Test
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multi-Colored Placido Disk Viability

NCT02148497
View directory record Official record
Conditions
Dry Eye, Sjogren's Disease, Healthy
Interventions
Multi-colored Placido disk imaging
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 89 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification

NCT04452279
View directory record Official record
Conditions
Ocular Surface Disease, Glaucoma, Open-Angle
Interventions
iStent or iStent inject implantation with concomitant cataract surgery
Device
Lead sponsor
Vance Thompson Vision
Other
Eligibility
22 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 16, 2026, 10:22 AM EDT
Active, not recruiting Phase 3 Interventional

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

NCT06245408
View directory record Official record
Conditions
Sjögren's Syndrome (SS)
Interventions
Dazodalibep, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
41
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye

NCT00765804
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
EGP-437 with EyeGate® II System, Sodium citrate buffer solution with EyeGate® II System
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Andover, Massachusetts • North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 3 Interventional

A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

NCT06493604
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Feasibility of IPL Combined With RF for Treatment of DED Due to MGD

NCT05487547
View directory record Official record
Conditions
Dry Eye Disease, Meibomian Gland Dysfunction
Interventions
IPL_RF_MGX
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
22 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
New York, New York • Harrisburg, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Lifitegrast to Treat Dry Eye

NCT01636206
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Lifitegrast, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
23
States / cities
Artesia, California • Hemet, California • Laguna Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)

NCT03633461
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-02 (simpinicline) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 16, 2026, 10:22 AM EDT
Withdrawn Not applicable Interventional

Omega 3 Supplementation and Ocular Surface Disease in Glaucoma

NCT01630551
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
Fishoil supplement, Olive Oil
Dietary Supplement
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT05370495
View directory record Official record
Conditions
Dry Eye Disease
Interventions
SY-201 Ophthalmic Solution 2.0%, SY-201 Ophthalmic Solution 1.0%, SY-201 Ophthalmic Solution 0.5%, SY-201 Ophthalmic Solution Vehicle
Drug
Lead sponsor
Seinda Pharmaceutical Guangzhou Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 16, 2026, 10:22 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction With FemtoSecond Laser

NCT01441895
View directory record Official record
Conditions
Cataract, Dry Eye
Interventions
Not listed
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Rockville Centre, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Nasal Spray Study in Sjogren's Dry Eye Disease

NCT05700422
View directory record Official record
Conditions
Sjogren's Syndrome, Dry Eye
Interventions
Varenicline Nasal Spray
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 16, 2026, 10:22 AM EDT